Company Profile

JMolner AS is an Estonia-based company primarily engaged in generic drug development for specialty generic pharmaceuticals. The Company also provides analytical chemistry services and cost-saving commercial stability solutions.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/10/26	€21.20	0.00%	1
21/10/26	€21.20	0.00%	130
19/10/26	€21.20	+3.92%	96
16/10/26	€20.40	-1.92%	51
15/10/26	€20.80	+0.97%	21

Delayed Quote Nasdaq Tallinn

More quotes

Market Closed - Nasdaq Tallinn 10:12:01 22/10/2026 +03			5-day change	1st Jan Change
21.20 ^EUR	0.00%		+1.92%	-24.29%

06-02	J. Molner AS acquired portfolio of US-marketed generic and specialty pharmaceutical products from Nordic Pharma, Inc.	CI
10/12/24	J. Molner AS Strengthens US Market Position with New Product Development Agreement	CI

06-02	J. Molner AS acquired portfolio of US-marketed generic and specialty pharmaceutical products from Nordic Pharma, Inc.	CI
10/12/24	J. Molner AS Strengthens US Market Position with New Product Development Agreement	CI
04/12/24	J. Molner AS Announces Approval and Upcoming Market Launch of Desoximetasone Ointment USP, 0.05%	CI
12/11/24	J. Molner AS Launches Lidocaine HCL Topical Solution USP, 4% in the United States	CI
22/10/24	J. Molner AS Appoints Sten Akel as Chief Financial Officer	CI
02/09/24	The J. Molner Company Appoints Dave Berthold as the New President North America	CI
30/04/24	J. Molner AS Gains US FDA Approval for First Estonian-Developed ANDA - Lidocaine Hydrochloride Topical Solution 4%	CI
04/03/24	J. Molner AS Enters into an Agreement with the US Centers for Medicaid and Medicare Services	CI
07/11/23	Certain Ordinary Shares of J. Molner AS are subject to a Lock-Up Agreement Ending on 7-NOV-2023.	CI
06/09/23	J. Molner AS Signs Licensing Agreement for Five Approved Drugs in the US	CI
07/11/22	J. Molner AS has completed an IPO in the amount of Ã‡1.199998 million.	CI
12/10/22	J. Molner AS has filed an IPO in the amount of Ã‡1.199998 million.	CI

09-30	J Molner : 2026 6 months consolidated unaudited interim report	PU
06-30	J Molner : Decisions of the shareholders - adoption of resolutions of the general meeting without calling a meeting	PU
06-17	J Molner : Chief Financial Officer of J Molner AS resigns	PU
06-08	J Molner : Notice of J. Molner AS Regarding the Adoption of a Shareholders' Resolution Without Convening a General Meeting	PU
06-08	J Molner : Audited Consolidated Annual Report 2025	PU

1 week	+1.92%
Current month	+1.92%
1 month	+23.98%
3 months	+10.99%
6 months	+6.00%
Current year	-24.29%

J. Molner Stock

Stocks

MOLNRIPO

EE3100109034

Pharmaceuticals

Chart: J. Molner

Latest news: J. Molner

Press Releases: J. Molner

Quotes and Performance

Price Extremes

Managers and Directors: J. Molner

Generic Pharmaceuticals

Company Profile

Quotes

1 week	20.4	21.2
1 month	17	26.4
Current year	10.2	28
1 year	10.2	30.8
3 years	10	32.6
5 years	5	32.6
10 years	5	32.6

Manager	Title	Age	Since
Jason Michael Atticus Grenfell-Gardner PRN	Corporate Officer/Principal	52	01/01/2015
Liina Kervemann DFI	Director of Finance/CFO	-	-
Erik Berlin PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Karita Sall BRD	Director/Board Member	52	-
Yoann John Ricau BRD	Director/Board Member	51	-
Martin Wilson BRD	Director/Board Member	49	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
J. MOLNER	0.00%	+1.92%	-22.63%	+75.93%	40.11M
ELI LILLY AND COMPANY	+1.64%	+5.13%	+58.93%	+117.36%	1,133B
JOHNSON & JOHNSON	+1.51%	+1.52%	+34.34%	+68.48%	621B
ABBVIE INC.	-0.21%	+0.47%	+23.08%	+94.76%	503B
ROCHE HOLDING AG	-0.96%	+2.00%	+38.07%	+63.04%	379B
MERCK & CO., INC.	+1.23%	+1.70%	+71.06%	+45.98%	370B
NOVARTIS AG	+0.94%	+1.43%	+21.78%	+51.12%	292B
ASTRAZENECA PLC	+1.40%	-0.02%	+1.24%	+25.70%	262B
AMGEN INC.	+0.87%	+2.87%	+45.56%	+57.22%	237B
GILEAD SCIENCES, INC.	+0.75%	+0.02%	+23.77%	+97.39%	190B
Average	+0.67%	+2.70%	+29.52%	+69.70%	398.8B
Weighted average by Cap.	+0.85%	+3.73%	+40.73%	+79.70%